# US 11,992,473 B2 · Compositions and methods for diagnosis and treatment of conditions related to the quality of aging and longevity > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 11,992,473 B2 - Document ID: US11992473B2 - Status: Granted - Kind: B2 - Application number: 17/086,165 - Filed: 2020-10-30 - Published: 2021-02-25 - Granted: 2024-05-28 - Earliest claimed: 2018-05-23 - Assignees: Epitracker, Inc. - Applicants: Epitracker, Inc. - Inventors: Stephanie Venn-Watson - Web page: https://patentgrep.com/patent/US11992473B2 ## CPC - A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00) - A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] - A23L 33/175: Amino acids - A61K 31/00: Medicinal preparations containing organic active ingredients - A61K 31/205: Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine - A61K 31/417: Imidazole-alkylamines, e.g. histamine, phentolamine - A61K 38/05: Dipeptides - A61P 3/02: Nutrients, e.g. vitamins, minerals - A61P 3/06: Antihyperlipidemics - A61P 3/10: for hyperglycaemia, e.g. antidiabetics - A61P 7/06: Antianaemics - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B) ## Abstract Compositions including metabolites that are small molecules, and salts and derivatives thereof, and methods for treatment or prophylaxis of conditions related to the quality of aging are provided, including compositions and methods for treating conditions that negatively impact longevity and the quality of aging, including inflammation, anemia, hyperglycemia, dyslipidemia, hyperinsulinemia, liver disease, iron overload, impaired skin integrity, wound healing, scarring, pain, allergies, sleep disorders and problems, and gastrointestinal disorders and problems. ## Claims ### Claim 1 A method for treatment or amelioration of aging or an aging-related condition negatively impacting longevity or quality of life, wherein the aging-related condition negatively impacting longevity or quality of life is autoimmunity, comprising: administering to a patient in need thereof pentadecanoylcarnitine, or pharmaceutically acceptable salts, solvates, stereoisomers, or esters thereof wherein the autoimmunity is rheumatoid arthritis, multiple sclerosis, Crohn disease, systemic lupus erythematosus, psoriasis, type 1 diabetes, hematological oncology, asthma, allergy, or ulcerative colitis. ### Claim 2 (depends on 1) The method of claim 1, wherein the pentadecanoylcarnitine or pharmaceutically acceptable salts thereof is administered in a unit dosage form, in a form of a supplement, in a form of a foodstuff, or in a form of a prescription therapeutic. ### Claim 3 (depends on 1) The method of claim 1, wherein the pentadecanoylcarnitine or pharmaceutically acceptable salts thereof is administered to a patient at from 0.5 mg to 50 mg, per 1 kg of body weight. ### Claim 4 (depends on 1) The method of claim 1, wherein the pentadecanoylcarnitine or pharmaceutically acceptable salts thereof is administered once per day. ### Claim 5 (depends on 1) The method of claim 1, wherein from 0.01 mg to 10000 mg of the pentadecanoylcarnitine or pharmaceutically acceptable salts thereof is administered. ### Claim 6 (depends on 1) The method of claim 1, wherein the autoimmunity is rheumatoid arthritis. ### Claim 7 (depends on 1) The method of claim 1, wherein the autoimmunity is multiple sclerosis. ### Claim 8 (depends on 1) The method of claim 1, wherein the autoimmunity is Crohn disease. ### Claim 9 (depends on 1) The method of claim 1, wherein the autoimmunity is systemic lupus. ### Claim 10 (depends on 1) The method of claim 1, wherein the autoimmunity is erythematosus. ### Claim 11 (depends on 1) The method of claim 1, wherein the autoimmunity is psoriasis. ### Claim 12 (depends on 1) The method of claim 1, wherein the autoimmunity is type 1 diabetes. ### Claim 13 (depends on 1) The method of claim 1, wherein the autoimmunity is hematological oncology. ### Claim 14 (depends on 1) The method of claim 1, wherein the autoimmunity is asthma. ### Claim 15 (depends on 1) The method of claim 1, wherein the autoimmunity is allergy. ### Claim 16 (depends on 1) The method of claim 1, wherein the autoimmunity is ulcerative colitis. ### Claim 17 (depends on 1) The method of claim 1, wherein the pentadecanoylcarnitine or pharmaceutically acceptable salts thereof is administered topically or to a mucous membrane. ### Claim 18 (depends on 1) The method of claim 1, wherein the pentadecanoylcarnitine or pharmaceutically acceptable salts thereof is administered with one or more therapeutic agents selected from the group consisting of antibacterial drugs, antiprotozoal drugs, antifungal drugs, antiviral drugs, spermicidal agents, prostaglandins, and steroids. ### Claim 19 (depends on 1) The method of claim 1, wherein the patient is a human. ### Claim 20 (depends on 1) The method of claim 1, wherein the patient is a mammal selected from the group consisting of dolphins, mice, rats, rabbits, guinea pigs, dogs, cats, sheep, goats, cows, horses, monkeys, chimpanzees, and apes.